<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3176">
  <stage>Registered</stage>
  <submitdate>11/05/2011</submitdate>
  <approvaldate>11/05/2011</approvaldate>
  <nctid>NCT01363011</nctid>
  <trial_identification>
    <studytitle>Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment</studytitle>
    <scientifictitle>A Phase 3 Open-label Safety Study of Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>GS-US-236-0118</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acquired Immunodeficiency Syndrome</healthcondition>
    <healthcondition>HIV Infections</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - E/C/F/TDF
Treatment: drugs - COBI
Treatment: drugs - ATV
Treatment: drugs - DRV
Treatment: drugs - NRTI

Experimental: E/C/F/TDF (Cohort 1) - Participants who have not received prior antiretroviral (ARV) treatment and who are virologically unsuppressed at baseline will initiate treatment with elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) single-tablet regimen (STR) for up to 96 weeks.
Following Week 96, participants continued their treatment until all participants discontinued from the study or commercial approval of E/C/F/TDF was received in the applicable country.

Experimental: COBI+PI+2 NRTI (Cohort 2) - Participants who have received prior ARV treatment and who are virologically suppressed at baseline will continue their treatment regimen, switching the regimen's pharmacoenhancer component from ritonavir to cobicistat (COBI), and continuing their existing protease inhibitor (PI; either atazanavir (ATV) or darunavir (DRV)) plus 2 nucleoside reverse transcriptase inhibitor (NRTI) regimen for up to 96 weeks.
Following Week 96, participants continued their treatment until all participants discontinued from the study or commercial approval of cobicistat was received in the applicable country.


Treatment: drugs: E/C/F/TDF
E/C/F/TDF (150/150/200/300 mg) STR administered orally once daily

Treatment: drugs: COBI
COBI 150 mg tablet administered with food orally once daily

Treatment: drugs: ATV
ATV 300 mg tablet administered orally once daily

Treatment: drugs: DRV
DRV 800 mg tablet administered orally once daily

Treatment: drugs: NRTI
Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC, 3TC, tenofovir disoproxil fumarate (TDF), or FTC/TDF, administered according to prescribing information.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) Using the Cockcroft-Gault (CG) Equation at Week 24 (Cohort 1) - Change from baseline in eGFR-CG equation at Week 24 was analyzed in Cohort 1 (treatment-naive).</outcome>
      <timepoint>Baseline; Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change From Baseline in eGFR-CG at Week 24 (Cohort 2) - Change from baseline in eGFR-CG equation at Week 24 was analyzed in Cohort 2 (treatment-experienced).</outcome>
      <timepoint>Baseline; Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change From Baseline in eGFR Using the Modification of Diet in Renal (MDRD) Equation at Week 24 (Cohort 1) - Change from baseline in eGFR-MDRD equation at Week 24 was analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area.</outcome>
      <timepoint>Baseline; Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change From Baseline in eGFR-MDRD at Week 24 (Cohort 2) - Change from baseline in eGFR-MDRD equation at Week 24 was analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area.</outcome>
      <timepoint>Baseline; Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change From Baseline in eGFR Using the Chronic Kidney Disease, Epidemiology Collaboration (CKD-EPI) Formula Based on Cystatin C Equation at Week 24 (Cohort 1) - Change from baseline in eGFR-CKD-EPI based on cystatin C equation (not adjusted for age, sex, and race) at Week 24 was analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area.</outcome>
      <timepoint>Baseline; Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change From Baseline in eGFR-CKD-EPI Formula Based on Cystatin C Equation at Week 24 (Cohort 2) - Change from baseline in eGFR-CKD-EPI based on cystatin C equation (not adjusted for age, sex, and race) at Week 24 was analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area.</outcome>
      <timepoint>Baseline; Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change From Baseline in eGFR-CKD-EPI Based on Cystatin C Equation, Adjusted at Week 24 (Cohort 1) - Change from baseline in eGFR-CKD-EPI based on cystatin C equation (adjusted for age, sex, and race) at Week 24 was analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area.</outcome>
      <timepoint>Baseline; Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change From Baseline in eGFR-CKD-EPI Based on Cystatin C Equation, Adjusted at Week 24 (Cohort 2) - Change from baseline in eGFR-CKD-EPI based on cystatin C equation (adjusted for age, sex, and race) at Week 24 was analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area.</outcome>
      <timepoint>Baseline; Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change From Baseline in Actual Glomerular Filtration Rate (aGFR) at Weeks 2, 4, and 24 (Cohort 1) - Change from baseline in aGFR at Weeks 2, 4, and 24 was analyzed in Cohort 1 (treatment-naive). aGFR was calculated using iohexol plasma clearance.</outcome>
      <timepoint>Baseline; Weeks 2, 4, and 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change From Baseline in aGFR at Weeks 2, 4, and 24 (Cohort 2) - Change from baseline in aGFR at Weeks 2, 4, and 24 was analyzed in Cohort 2 (treatment-experienced). aGFR was calculated using iohexol plasma clearance.</outcome>
      <timepoint>Baseline; Weeks 2, 4, and 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 24 (Cohort 1) - The percentage of participants with HIV-1 RNA &lt; 50 copies/mL at Week 24 was analyzed in Cohort 1 (treatment-naive) using the FDA snapshot analysis algorithm.</outcome>
      <timepoint>Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 24 (Cohort 2) - The percentage of participants with HIV-1 RNA &lt; 50 copies/mL at Week 24 was analyzed in Cohort 2 (treatment-experienced) using the FDA snapshot analysis algorithm.</outcome>
      <timepoint>Week 24</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in eGFR-CG at Weeks 48 and 96 (Cohort 1) - Change from baseline in eGFR-CG at Weeks 48 and 96 were analyzed in Cohort 1 (treatment-naive). This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters.</outcome>
      <timepoint>Baseline; Weeks 48 and 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in eGFR-CG at Weeks 48 and 96 (Cohort 2) - Change from baseline in eGFR-CG at Weeks 48 and 96 were analyzed in Cohort 2 (treatment-experienced). This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters.</outcome>
      <timepoint>Baseline; Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in eGFR-MDRD at Weeks 48 and 96 (Cohort 1) - Change from baseline in eGFR-MDRD at Weeks 48 and 96 were analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters.</outcome>
      <timepoint>Baseline; Weeks 48 and 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in eGFR-MDRD at Weeks 48 and 96 (Cohort 2) - Change from baseline in eGFR-MDRD at Weeks 48 and 96 were analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters.</outcome>
      <timepoint>Baseline; Weeks 48 and 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in eGFR-CKD-EPI Based on Cystatin C Equation at Weeks 48 and 96 (Cohort 1) - Change from baseline in eGFR-CKD-EPI based on cystatin C equation (not adjusted for age, sex, and race) at Weeks 48 and 96 were analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters.</outcome>
      <timepoint>Baseline; Weeks 48 and 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in eGFR-CKD-EPI Based on Cystatin C Equation at Weeks 48 and 96 (Cohort 2) - Change from baseline in eGFR-CKD-EPI based on cystatin C equation (not adjusted for age, sex, and race) at Weeks 48 and 96 were analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters.</outcome>
      <timepoint>Baseline; Weeks 48 and 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in eGFR-CKD-EPI Based on Cystatin C Equation (Adjusted) at Weeks 48 and 96 (Cohort 1) - Change from baseline in eGFR-CKD-EPI based on cystatin C equation (adjusted for age, sex, and race) at Weeks 48 and 96 were analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters.</outcome>
      <timepoint>Baseline; Weeks 48 and 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in eGFR-CKD-EPI Based on Cystatin C Equation (Adjusted) at Weeks 48 and 96 (Cohort 2) - Change from baseline in eGFR-CKD-EPI based on cystatin C equation (adjusted for age, sex, and race) at Weeks 48 and 96 were analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters.</outcome>
      <timepoint>Baseline; Weeks 48 and 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Weeks 48 and 96 (Cohort 1) - The percentage of participants with HIV-1 RNA &lt; 50 copies/mL at Weeks 48 and 96 were analyzed in Cohort 1 (treatment-naive) using the FDA snapshot analysis algorithm.</outcome>
      <timepoint>Weeks 48 and 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Weeks 48 and 96 (Cohort 2) - The percentage of participants with HIV-1 RNA &lt; 50 copies/mL at Weeks 48 and 96 were analyzed in Cohort 2 (treatment-experienced) using the FDA snapshot analysis algorithm.</outcome>
      <timepoint>Weeks 48 and 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Who Experienced Adverse Events (Cohort 1) - Adverse events (AEs) occurring from baseline up to 30 days following the last dose of study drug were summarized for Cohort 1 (treatment-naive). A participant was counted once if they had a qualifying event.</outcome>
      <timepoint>Up to 147 weeks plus 30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Who Experienced Adverse Events (Cohort 2) - Adverse events (AEs) occurring from baseline up to 30 days following the last dose of study drug were summarized for Cohort 2 (treatment-experienced). A participant was counted once if they had a qualifying event.</outcome>
      <timepoint>Up to 166 weeks plus 30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Who Experienced Graded Laboratory Abnormalities (Cohort 1) - Laboratory abnormalities were summarized for Cohort 1 (treatment-naive) and were defined as values that increased at least one toxicity grade from baseline at any time postbaseline up to and including the date of last dose of study drug plus 30 days. A participant was counted once if they had a qualifying event.</outcome>
      <timepoint>Up to 147 weeks plus 30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Who Experienced Graded Laboratory Abnormalities (Cohort 2) - Laboratory abnormalities were summarized for Cohort 2 (treatment-experienced) and were defined as values that increased at least one toxicity grade from baseline at any time postbaseline up to and including the date of last dose of study drug plus 30 days. A participant was counted once if they had a qualifying event.</outcome>
      <timepoint>Up to 166 weeks plus 30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Pharmacokinetics of COBI: AUCtau (Cohort 1) - AUCtau was analyzed for Cohort 1 (treatment-naive) and was defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval).</outcome>
      <timepoint>Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Pharmacokinetics of COBI: AUCtau (Cohort 2) - AUCtau was analyzed for Cohort 2 (treatment-experienced) and was defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval).</outcome>
      <timepoint>Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Pharmacokinetics of COBI: Cmax (Cohort 1) - Cmax was analyzed for Cohort 1 (treatment-naive) and was defined as the maximum observed concentration of drug in plasma.</outcome>
      <timepoint>Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Pharmacokinetics of COBI: Cmax (Cohort 2) - Cmax was analyzed for Cohort 2 (treatment-experienced) and was defined as the maximum observed concentration of drug in plasma.</outcome>
      <timepoint>Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Pharmacokinetics of COBI: Ctau (Cohort 1) - Ctau was analyzed for Cohort 1 (treatment-naive) and was defined as the observed drug concentration at the end of the dosing interval.</outcome>
      <timepoint>Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Pharmacokinetics of COBI: Ctau (Cohort 2) - Ctau was analyzed for Cohort 2 (treatment-experienced) and was defined as the observed drug concentration at the end of the dosing interval.</outcome>
      <timepoint>Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Pharmacokinetics of COBI: Tmax (Cohort 1) - Tmax was analyzed for Cohort 1 (treatment-naive) and was defined as the time of Cmax.</outcome>
      <timepoint>Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Pharmacokinetics of COBI: Tmax (Cohort 2) - Tmax was analyzed for Cohort 2 (treatment-experienced) and was defined as the time of Cmax.</outcome>
      <timepoint>Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Pharmacokinetics of COBI: t1/2 (Cohort 1) - t1/2 was analyzed for Cohort 1 (treatment-naive) and was defined as the estimate of the terminal elimination half-life of the drug.</outcome>
      <timepoint>Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Pharmacokinetics of COBI: t1/2 (Cohort 2) - t1/2 was analyzed for Cohort 2 (treatment-experienced) and was defined as the estimate of the terminal elimination half-life of the drug.</outcome>
      <timepoint>Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Cohort 1 (treatment-naive)

          -  Plasma HIV-1 RNA levels = 1,000 copies/mL at screening

          -  Screening genotype report must show sensitivity to FTC and TDF

          -  No prior use of any approved or investigational antiretroviral drug for any length of
             time

        Cohort 2 (treatment-experienced, pharmacoenhancer switch)

          -  Subjects must be receiving ATV 300 mg/ritonavir (RTV) 100 mg plus 2 NRTIs OR DRV 800
             mg/RTV 100 mg plus 2 NRTIs for at least 6 months prior to screening

          -  Plasma HIV-1 RNA concentrations at undetectable levels in the 6 months preceding the
             screening visit and have HIV-1 RNA &lt; 50 copies/mL at screening

          -  Subjects experiencing intolerance to RTV (as determined by the investigator)

        Both groups

          -  The ability to understand and sign a written informed consent form

          -  Normal ECG

          -  Mild to moderate renal function

          -  Stable renal function

          -  Hepatic transaminases (AST and ALT) = 5 x the upper limit of the normal range (ULN)

          -  Total bilirubin = 1.5 mg/dL, or normal direct bilirubin (subjects with documented
             Gilbert's Syndrome or hyperbilirubinemia due to atazanavir therapy may have total
             bilirubin up to 5 x ULN)

          -  Adequate hematologic function

          -  Serum amylase = 5 x ULN

          -  Males and females of childbearing potential must agree to utilize highly effective
             contraception methods from screening throughout the duration of study treatment and
             for 30 days following the last dose of study drug

          -  Age = 18 years</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  New AIDS-defining condition diagnosed within the 30 days prior to screening

          -  Receiving drug treatment for hepatitis C, or anticipated to receive treatment for
             hepatitis C

          -  Subjects experiencing decompensated cirrhosis

          -  Females who are breastfeeding

          -  Positive serum pregnancy test (female of childbearing potential)

          -  Implanted defibrillator or pacemaker

          -  Current alcohol or substance use judged by the investigator to potentially interfere
             with subject study compliance

          -  History of malignancy within the past 5 years or ongoing malignancy other than
             cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, noninvasive cutaneous
             squamous carcinoma

          -  Active, serious infections (other than HIV-1 infection) requiring parenteral
             antibiotic or antifungal therapy within 30 days prior to baseline

          -  Receiving ongoing therapy with any of medications contraindicated for use with
             elvitegravir (EVG), COBI, FTC, TDF, ATV, DRV; or subjects with any known allergies to
             the excipients of E/C/F/TDF STR, COBI tablets, ATV capsules or DRV tablets or
             contraindicated for the 2 NRTIs as part of the PI/co regimen

          -  Participation in any other clinical trial without prior approval

          -  Any other clinical condition or prior therapy that would make the subject unsuitable
             for the study or unable to comply with the dosing requirements</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>106</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Taylor Square Private Clinic - Darlinghurst</hospital>
    <hospital>Infectious Diseases Unit - The Alfred Hospital - Melbourne</hospital>
    <hospital>Holdsworth House Medical Practice - Sydney</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>3004 - Melbourne</postcode>
    <postcode>2010 - Sydney</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Graz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Montreal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Dominican Republic</country>
      <state>Santo Domingo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>DÃ¼sseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Guadalajara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>San Juan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Brighton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is to characterize the effect of cobicistat-based regimens on parameters of renal
      function in participants with HIV infection and who have mild to moderate renal impairment,
      and to assess the safety and tolerability of the regimens in order to generate appropriate
      dosing recommendations.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01363011</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Javier Szwarcberg, MD</name>
      <address>Gilead Sciences</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>